BMS-986020

DRUG5 trials

Sponsors

Bristol-Myers Squibb

Conditions

Drug-drug Interaction StudyIdiopathic Pulmonary FibrosisImmunologyImmunosuppression For DiseaseScleroderma

Phase 1

To Evaluate The Relationship Between Plasma Drug Levels And Receptor Binding in Lung Using PET (Positron Emission Tomography) In Healthy Volunteers

CompletedNCT02017730

Bristol-Myers SquibbImmunology

Start: 2014-01-31End: 2015-01-31Updated: 2015-07-07

Drug Interaction Study With Rosuvastatin

CompletedNCT02101125

Bristol-Myers SquibbImmunosuppression For Disease

Start: 2014-03-31End: 2014-05-31Updated: 2014-06-17

A Phase 1 Drug-drug Interaction Study in Healthy Volunteers

CompletedNCT02227173

Bristol-Myers SquibbDrug-drug Interaction Study

Start: 2014-09-30End: 2014-11-30Updated: 2014-11-18

Phase 2

Safety and Efficacy of a Lysophosphatidic Acid Receptor Antagonist in Idiopathic Pulmonary Fibrosis

CompletedNCT01766817

Bristol-Myers SquibbIdiopathic Pulmonary Fibrosis

Start: 2013-01-31End: 2016-02-29Updated: 2020-08-11

A Double-Blinded Study to Evaluate the Safety, Tolerability, and Efficacy of BMS-986020 Versus Placebo in Diffuse Cutaneous Systemic Sclerosis (dcSSc)

WithdrawnNCT02588625

Bristol-Myers SquibbScleroderma

Start: 2016-02-29End: 2019-10-31Updated: 2016-07-22

Related Papers

An adjudication algorithm for respiratory-related hospitalisation in idiopathic pulmonary fibrosis

ERJ Open Research2024-01-013 citations

LPA1 antagonist BMS-986020 changes collagen dynamics and exerts antifibrotic effects in vitro and in patients with idiopathic pulmonary fibrosis

Respiratory Research2022-03-1854 citations

Phase 2 trial design of BMS-986278, a lysophosphatidic acid receptor 1 (LPA<sub>1</sub>) antagonist, in patients with idiopathic pulmonary fibrosis (IPF) or progressive fibrotic interstitial lung disease (PF-ILD)

BMJ Open Respiratory Research2021-12-0150 citations

Randomized, Double-Blind, Placebo-Controlled, Phase 2 Trial of BMS-986020, a Lysophosphatidic Acid Receptor Antagonist for the Treatment of Idiopathic Pulmonary Fibrosis

CHEST Journal2018-09-07201 citations